MarketCapExport financials
Tekla Life Sciences Investors (HQL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
TelegramTekla Life Sciences Investors Income Statement 2020-2011 | HQL
Brief overview of revenue and earnings at Tekla Life Sciences Investors
The comparison covers a five-year financial horizon. Tekla Life Sciences Investors reported revenue of 1.3 million dollars in 2015 and 124 million dollars by 2020. The five-year change reached +9281.7%, while CAGR stood at 148%. Revenue growth reflects a pronounced phase of business expansion.
The five-year change in net income was +203.8%: from $40.5 million to $123 million. The latest figure was the best within the selected horizon.
Over the period, capitalization shifted from $513 million to $392 million (−23.6%). Investors remain cautious despite better financial results.
Financial takeaway
The results present an uneven picture without one dominant signal. The constructive conclusion rests on a larger revenue base and net-income growth. The overall view is constrained by declining capitalization. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Tekla Life Sciences Investors
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
392 M | 369 M | 392 M | 439 M | 355 M | 513 M | 454 M | 285 M | 215 M | 163 M |
Shares |
23.2 M | 23.2 M | 22.4 M | 21.6 M | 20.7 M | 19.7 M | 19 M | 15 M | 14.4 M | 14.6 M |
Net Income |
123 M | -70.5 M | 28.7 M | 68.6 M | -11.9 M | 40.5 M | 89.3 M | 84.6 M | 77.6 M | 37.5 M |
Revenue |
124 M | 2.44 M | 1.99 M | 1.68 M | 1.44 M | 1.32 M | 880 K | 520 K | 2.14 M | 570 K |
EBITDA |
- | -138 M | 60.9 M | 141 M | -20 M | 85.7 M | 182 M | 172 M | 157 M | 37.5 M |
Operating Expenses |
- | 1.14 M | 1.16 M | 1.26 M | 679 K | 397 K | 500 K | 590 K | 950 K | 1.35 M |
General and Administrative Expenses |
751 K | 702 K | 691 K | 832 K | 550 K | 254 K | 370 K | 440 K | 750 K | 1.15 M |
Annual performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Tekla Life Sciences Investors (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
China
Canada
Cayman-islands
